Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -115.18% is 39% above its 5-year average of -190.07%, near the high end of its 5-year range (-738.05%–19.30%).
59.21% above its 12-month average of -282.37%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -43.67%.
NET PROFIT MARGIN
-115.18%
NET PROFIT MARGIN AVG TTM
-282.37%
NET PROFIT MARGIN AVG 3Y
-294.77%
NET PROFIT MARGIN AVG 5Y
-190.07%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+59.21%
CURRENT VS 3Y AVG
+60.93%
CURRENT VS 5Y AVG
+39.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-44200.00%
vs the sector median at left
OmniAb, Inc.
Market Cap
$621.21M
Net Profit Margin
-115.18%
TTM Avg
-282.37%
3Y Avg
-294.77%
5Y Avg
-190.07%
Market Cap
$623.06M
Net Profit Margin
-93.86%
TTM Avg
-99.06%
3Y Avg
-127.16%
5Y Avg
-138.22%
Market Cap
$611.57M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$632.51M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$631.35M
Net Profit Margin
42.82%
TTM Avg
-184.34%
3Y Avg
-199.96%
5Y Avg
-154.29%
Market Cap
$633.06M
Net Profit Margin
-4613.11%
TTM Avg
-5454.52%
3Y Avg
-2727.26%
5Y Avg
-1829.08%
Market Cap
$598.37M
Net Profit Margin
33.36%
TTM Avg
4.18%
3Y Avg
-43.84%
5Y Avg
-3.40%
Market Cap
$591.38M
Net Profit Margin
-11.48%
TTM Avg
-11.55%
3Y Avg
-24.81%
5Y Avg
-19.75%
Market Cap
$656.86M
Net Profit Margin
-194.74%
TTM Avg
-217471.40%
3Y Avg
-109716.20%
5Y Avg
-73279.44%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OmniAb, Inc. (OABI) | $621.21M | -115.18% | -282.37% | -294.77% | -190.07% |
| SOPHiA GENETICS S.A. (SOPH)vs › | $623.06M | -93.86% | -99.06% | -127.16% | -138.22% |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aura Biosciences, Inc. (AURA)vs › | $632.51M | 0.00% | 0.00% | 0.00% | 0.00% |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $631.35M | 42.82% | -184.34% | -199.96% | -154.29% |
| Prime Medicine, Inc. (PRME)vs › | $633.06M | -4613.11% | -5454.52% | -2727.26% | -1829.08% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | 33.36% | 4.18% | -43.84% | -3.40% |
| AngioDynamics, Inc. (ANGO)vs › | $591.38M | -11.48% | -11.55% | -24.81% | -19.75% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.86M | -194.74% | -217471.40% | -109716.20% | -73279.44% |
| Starling Oncology, Inc. (STLN)vs › | $658.68M | -6.18% | -12.06% | -12.06% | -12.06% |
Operating Margin
-383.1%
Net Profit Margin
-115.2%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -43.67% |
| 2026-03-31 | -53.47% |
| 2025-12-31 | -169.28% |
| 2025-09-30 | -738.05% |
| 2025-06-30 | -407.36% |
| 2025-03-31 | -438.13% |
| 2024-12-31 | -120.96% |
| 2024-09-30 | -392.45% |
| 2024-06-30 | -179.03% |
| 2024-03-31 | -498.84% |
| 2023-12-31 | -291.44% |
| 2023-09-30 | -287.35% |
| 2023-06-30 | -212.04% |
| 2023-03-31 | -36.05% |
| 2022-12-31 | 19.30% |
| 2022-09-30 | -182.29% |
| 2022-06-30 | -142.74% |
| 2022-03-31 | -65.28% |
| 2021-12-31 | -20.10% |
| 2021-09-30 | -125.70% |
| 2021-06-30 | -154.43% |
| 2021-03-31 | -121.90% |
| 2020-12-31 | -1.19% |
| 2020-09-30 | -134.05% |
